Table 1.

The Various Clinical and Therapeutic Particularities of ET According to JAK2 or CALR Molecular Subtypes.

JAK2V617F-mutated ET CALR-mutated ET
Age, sex Older Younger, M>F
Blood counts Hemoglobin Higher Lower
Platelet Lower Higher
White blood count Higher Lower
Serum erythropoietin level Lower Higher
Thrombotic risk Higher Lower
Polycythemic risk Cumulative risk 29% at 15 years No transformation to PV
MF transformation risk Conflicting results
Overall survival (OS) Long-term OS similar to that in CALR-mutated ET Long-term OS similar to that in JAK2V617F-mutated ET
Treatment implications ET patients with CALR mutations are at a lower risk of thrombotic complications compared to those with JAK2 mutations; however, recommendations regarding modifications of current treatment based on mutation status have not been developed yet
RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 October; 5(4): e0035. ISSN: 2076-9172
Published online 2014 October 29. doi: 10.5041/RMMJ.10169.